Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Three patients with refractory pemphigus vulgaris improved after rituximab, an anti-CD20 monoclonal antibody directed against B cells. Treatment was well tolerated immediately, but one patient developed fatal pneumocystis carinii pneumonia. Serious infections have occurred in several pemphigus patients treated with rituximab and immunosuppressive medications, warranting further evaluation of risk-benefit ratio.

Original languageEnglish (US)
Pages (from-to)817-819
Number of pages3
JournalJournal of the American Academy of Dermatology
Volume51
Issue number5
DOIs
StatePublished - Nov 2004

Fingerprint

Pemphigus
Anti-Idiotypic Antibodies
Monoclonal Antibodies
Pneumocystis Pneumonia
Immunosuppressive Agents
B-Lymphocytes
Therapeutics
Odds Ratio
Infection
Rituximab

ASJC Scopus subject areas

  • Dermatology

Cite this

@article{d53e5ce6f1334d5cb8a6b4b13a5c9dae,
title = "Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)",
abstract = "Three patients with refractory pemphigus vulgaris improved after rituximab, an anti-CD20 monoclonal antibody directed against B cells. Treatment was well tolerated immediately, but one patient developed fatal pneumocystis carinii pneumonia. Serious infections have occurred in several pemphigus patients treated with rituximab and immunosuppressive medications, warranting further evaluation of risk-benefit ratio.",
author = "Lynne Morrison",
year = "2004",
month = "11",
doi = "10.1016/j.jaad.2004.06.007",
language = "English (US)",
volume = "51",
pages = "817--819",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)

AU - Morrison, Lynne

PY - 2004/11

Y1 - 2004/11

N2 - Three patients with refractory pemphigus vulgaris improved after rituximab, an anti-CD20 monoclonal antibody directed against B cells. Treatment was well tolerated immediately, but one patient developed fatal pneumocystis carinii pneumonia. Serious infections have occurred in several pemphigus patients treated with rituximab and immunosuppressive medications, warranting further evaluation of risk-benefit ratio.

AB - Three patients with refractory pemphigus vulgaris improved after rituximab, an anti-CD20 monoclonal antibody directed against B cells. Treatment was well tolerated immediately, but one patient developed fatal pneumocystis carinii pneumonia. Serious infections have occurred in several pemphigus patients treated with rituximab and immunosuppressive medications, warranting further evaluation of risk-benefit ratio.

UR - http://www.scopus.com/inward/record.url?scp=8744228329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8744228329&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2004.06.007

DO - 10.1016/j.jaad.2004.06.007

M3 - Article

VL - 51

SP - 817

EP - 819

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 5

ER -